Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Bariatric Surgery: Waiting Times Too Long In Canada
Obesity is now acknowledged as a chronic disease with a number of related complications, and its prevalence has reached alarming epidemic proportions. While bariatric surgery is effective at treating the disease, access to this procedure is still too limited in Canada. The latest article published by Dr. Nicolas Christou, of the McGill University Health Centre (MUHC), in the June issue of the Canadian Journal of Surgery assesses the waiting times for this procedure.
generic viagra online
Large Abdominal Wall Lipoma Causes Bowel Obstruction
Proteus syndrome is a complex disorder associated with varied, disproportionate, asymmetric overgrowth of many body parts and unregulated adipose tissue. The overgrowth seen in Proteus syndrome is progressive and difficult to manage. Patients with Proteus syndrome require repeated treatment for the progressive overgrowth of tissue over a long period. Aggressive treatment may cause severe functional and cosmetic consequences, so surgical intervention is often delayed until it is absolutely necessary.
News of the day
Baptist Conference Addresses HIV/AIDS In Black Community
Fear, religious beliefs and cultural differences are among the reasons why blacks do not get tested for HIV, participants of the National Baptist Convention USA"s annual Congress of Christian Education conference being held in Detroit, said on Monday, the Detroit Free Press reports. As part of the five-day conference, religious leaders discussed ways to address the high rates of HIV and AIDS among the black community. Participants also said that concerns of racism by medical professionals may be a reason why blacks do not get tested. Simone Phillips of the St. Louis chapter of the American Red Cross said, "A lot of people are leery" in the black community and "we [need] to get rid of the stigma" surrounding HIV/AIDS (Warikoo, Detroit Free Press, 6/23).
Mental Health

Zysolin(TM) Pre-clinical Data Supports Once-a-day Dosing In Humans

AlphaRx (OTC BB:ALRX) is pleased to report a significant breakthrough in the development of Zysolin(TM), an inhaled Tobramycin nanoparticle formulation utilizing the company"s proprietary drug delivery platform, and intended for the adjunctive treatment of Pseudomonas Aeruginosa Pneumonia in intubated and mechanically-ventilated patients (VAP). In a recent pivotal animal PK (pharmacokinetic) study, Zysolin(TM) delivered 300% more drug to lung tissue than free drug, when utilizing the same delivery method. This data demonstrates that Zysolin(TM) provides superior lung tissue penetration and a release profile which supports once-a-day human dosing frequency. The study data will be presented, by invitation, to the upcoming July meeting of the Controlled Release Society Conference in Copenhagen, Denmark. Dr. Michael Weisspapir, MD, PhD, Chief Medical Scientist of AlphaRx commented, "As a result of this pre-clinical data, we anticipate that the demonstrated superiority over free drug availability will result in higher drug concentrations in lung tissue, enhancing clinical efficacy for VAP patients in vivo." About Zysolin(TM) Zysolin(TM) is a Tobramycin compound, encapsulated in AlphaRx"s Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin(TM) improves the intracellular activity of Tobramycin - in layman"s term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin(TM), Tobramycin, has a long-standing and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin(TM) will have an attractive safety, tolerability and efficacy profile when compared to injectible Tobramycin. About AlphaRx Inc. AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development. Forward Looking Statements: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies. AlphaRx Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009